Scinai Immunotherapeutics (SCNI) Return on Sales (2024 - 2026)

Scinai Immunotherapeutics (SCNI) has 3 years of Return on Sales data on file, last reported at 0.05% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 2.0% year-over-year to 0.05%; the trailing twelve-month figure through Mar 2026 stood at 0.04% (changed N/A YoY), and the FY2025 full-year result was 0.16%, up 33.0% from the prior year.
• Return on Sales grew to 0.05% in Q1 2026, from 0.12% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q1 2025 to a low of 0.18% in Q4 2024.
• A 3-year average of 0.1% and a median of 0.12% in 2025 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 2 bps in 2026, while the deepest fall reached 2 bps in 2026.
• Tracing SCNI's Return on Sales over 3 years: stood at 0.18% in 2024, then soared by 33 bps to 0.12% in 2025, then soared by 57 bps to 0.05% in 2026.
• Business Quant data shows SCNI's Return on Sales at 0.05% in Q1 2026, 0.12% in Q2 2025, and 0.03% in Q1 2025.